Alfonso Massimiliano Ferrara

Alfonso Massimiliano Ferrara

Auto-generated profile, based on publicly available information

Alfonso Massimiliano Ferrara

Department of Medicine, The University of Chicago, Chicago, IL 60637, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MDMonica Dentice
Monica Dentice
VCViviana Cordeddu
Viviana Cordeddu
ARAnnamaria Rosica
Annamaria Rosica
AFAlfonso Massimiliano Ferrara
Alfonso Massimiliano Ferrara
LSLibero Santarpia
Libero Santarpia
Paolo Emidio MacchiaPaolo Emidio Macchia
Paolo Emidio Macchia
Context: Congenital hypothyroidism (CH) is a common endocrine disorder with an incidence of 1:3000–4000 at birth. In 80–85% of cases, CH is caused by defects in thyroid organogenesis, resulting in absent, ectopically located, and/or severely reduced gland [thyroid dysgenesis (TD)]. Mutations in genes controlling thyroid development have demonstrated that in a few cases, TD is a Mendelian trait. However, accumulating evidence supports the view that the genetics of TD are complex, possibly with a polygenic/multifactorial basis. A higher prevalence of congenital heart disease has been documented in children with CH than in the general population. Such an association suggests a possible pathogenic role of genes involved in both heart and thyroid development. NKX2–5 encodes a homeodomain-containing transcription factor with a major role in heart development, and mutations affecting this gene have been reported in individuals with congenital heart disease. Objective: In the present work we investigated the possible involvement of NKX2–5 mutations in TD. Results: Our results indicate that Nkx2–5−/− embryos exhibit thyroid bud hypoplasia, providing evidence that NKX2–5 plays a role in thyroid organogenesis and that NKX2–5 mutations contribute to TD. NKX2–5 mutational screening in 241 patients with TD allowed the identification of three heterozygous missense changes (R25C, A119S, and R161P) in four patients with TD. Functional characterization of the three mutations demonstrated reduced DNA binding and/or transactivation properties, with a dominant-negative effect on wild-type NKX2–5. Conclusion: Our results suggest a previously unknown role of NKX2–5 in the pathogenesis of TD.

1 October 2015 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
TPTheodora Pappa
Theodora Pappa
AFAlfonso Massimiliano Ferrara
Alfonso Massimiliano Ferrara
SRSamuel Refetoff
Samuel Refetoff

1 April 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
AFAlfonso Massimiliano Ferrara
Alfonso Massimiliano Ferrara
KOKazumichi Onigata
Kazumichi Onigata
OEOya Ercan
Oya Ercan
HWHelen Woodhead
Helen Woodhead
RWRoy E. Weiss
Roy E. Weiss
SRSamuel Refetoff
Samuel Refetoff
Context: The most common cause of resistance to thyroid hormone (RTH) is heterozygous thyroid hormone receptor β (THRB) gene mutations. Homozygous mutations in the THRB gene are a rare event. Objective: In this study, the clinical findings of three new patients (belonging to two families) homozygous for mutations in the THRB gene are compared to three other families in which affected individuals lack a normal TRβ. Methods: We conducted clinical studies and genetic analyses. Results: The clinical presentation in all three homozygous subjects was unusually severe; their phenotype was characterized by compromised intellectual development, tachycardia, goiter, growth retardation, and hearing loss. This was comparable with one other reported patient homozygous for mutant TRβ, but not in RTH due to THRB gene deletions. Conclusion: We report three new subjects, from two families, in whom RTH was associated with homozygous mutations in the THRB gene. They represent an important addition to the single known patient homozygous for a mutant TRβ. The clinical and laboratory abnormalities indicate a strong dominant-negative effect and are in agreement with data obtained from mice expressing a mutant Thrb in both alleles. This report strengthens the concept that the mutated TRβ interferes with the function of the TRα1 in humans.

19 April 2016 in Endocrine
Verified
Journal Article
Closed access
PDF file
NAN. M. Albiger
N. M. Albiger
DANIELA REGAZZODANIELA REGAZZO
DANIELA REGAZZO
BRB. Rubin
B. Rubin
AFA. M. Ferrara
A. M. Ferrara
SRS. Rizzati
S. Rizzati
CSCarla Scaroni
Carla Scaroni

21 May 2013 in Endocrinology
Verified
Journal Article
Open access
PDF file
AFAlfonso Massimiliano Ferrara
Alfonso Massimiliano Ferrara
XLXiao-Hui Liao
Xiao-Hui Liao
PGPilar Gil-Ibáñez
Pilar Gil-Ibáñez
TMTeresa Marcinkowski
Teresa Marcinkowski
JBJuan Bernal
Juan Bernal
SRSamuel Refetoff
Samuel Refetoff
Patients with the monocarboxylate transporter 8 (MCT8) deficiency syndrome present with a severe psychomotor retardation and abnormal serum thyroid hormone (TH) levels, consisting of high T3 and low T4 and rT3. Mice deficient in Mct8 replicate the thyroid phenotype of patients with the MCT8 gene mutations. We analyzed the serum TH levels and action in the cerebral cortex and in the liver during the perinatal period of mice deficient in Mct8 to assess how the thyroid abnormalities of Mct8 deficiency develop and to study the thyroidal status of specific tissues. During perinatal life, the thyroid phenotype of Mct8-deficient mice is different from that of adult mice. They manifest hyperthyroxinemia at embryonic day 18 and postnatal day 0. This perinatal hyperthyroxinemia is accompanied by manifestations of TH excess as evidenced by a relative increase in the expression of genes positively regulated by T3 in both the cerebral cortex and liver. An increased tissue accumulation of T4 and T3 and the expression of TH alternative transporters, including Lat1, Lat2, Oatp1c1, and Oatp3a1 in the cortex and Lat2 and Oatp1b2 in the liver, suggested that Mct8 deficiency either directly interferes with tissue efflux of TH or indirectly activates other transporters to increase TH uptake. This report is the first to identify that the ontogenesis of TH abnormalities in Mct8-deficient mice manifests with TH excess in the perinatal period.

1 September 2018 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
TKTobias Krauss
Tobias Krauss
AFAlfonso Massimiliano Ferrara
Alfonso Massimiliano Ferrara
TLThera P Links
Thera P Links
Ulrich Friedrich WellnerUlrich Friedrich Wellner
Ulrich Friedrich Wellner
IBIrina Bancos
Irina Bancos
BBBirke Bausch
Birke Bausch
Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel–Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-PanNET-Registry to assess data for risks for metastases, survival and long-term outcomes to provide best management recommendations. Of 2330 VHL patients, 273 had a total of 484 PanNETs. Median age at diagnosis of PanNET was 35 years (range 10–75). Fifty-five (20%) patients had metastatic PanNETs. Metastatic PanNETs were significantly larger (median size 5 vs 2 cm; P < 0.001) and tumor volume doubling time (TVDT) was faster (22 vs 126 months; P = 0.001). All metastatic tumors were ≥2.8 cm. Codons 161 and 167 were hotspots for VHL germline mutations with enhanced risk for metastatic PanNETs. Multivariate prediction modeling disclosed maximum tumor diameter and TVDT as significant predictors for metastatic disease (positive and negative predictive values of 51% and 100% for diameter cut-off ≥2.8 cm, 44% and 91% for TVDT cut-off of ≤24 months). In 117 of 273 patients, PanNETs >1.5 cm in diameter were operated. Ten-year survival was significantly longer in operated vs non-operated patients, in particular for PanNETs <2.8 cm vs ≥2.8 cm (94% vs 85% by 10 years; P = 0.020; 80% vs 50% at 10 years; P = 0.030). This study demonstrates that patients with PanNET approaching the cut-off diameter of 2.8 cm should be operated. Mutations in exon 3, especially of codons 161/167 are at enhanced risk for metastatic PanNETs. Survival is significantly longer in operated non-metastatic VHL-PanNETs.